Parkinson’s disease: Prexton Therapeutics, participated by Ysios Capital, completes phase 1 clinical trial

by Ysios Capital

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

Read more

CVRx® Secures $113 Million in New Financing

by Ysios Capital

CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Stat Diagnostica announces 25 Million Euros in Series C Financing led by Gilde Healthcare

by Ysios Capital

Led by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Ventur...

Read more

La Caixa leads an investment round in Inbiomotion with the participation of Ysios Capital

by Professional Newco

The fund is driven by ”la Caixa” and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme an...

Read more

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more

Sanifit raises €36.6M ($41.3M) in Series C financing round

by Ysios Capital

Financing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Horizon pone en marcha una planta punter...

by Horizon Products

Horizon ha puesto en funcionamiento una nueva planta dedicada íntegra...

Photos Stream